Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1648 1671
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17614602 | METHODS AND COMPOSITIONS FOR MODULATING IMMUNE RESPONSES | Final Rejection | Massachusetts Institute of Technology |
| 18014645 | SAMPLING KITS AND METHODS FOR DETECTING RESPIRATORY PATHOGENS | Non-Final OA | SEEGENE, INC. |
| 18011678 | METHOD FOR PROVIDING PREPARATION FOR DETECTING TARGET NUCLEIC ACID SEQUENCE IN SPECIMEN | Final Rejection | SEEGENE, INC. |
| 18014507 | DETECTING AND QUANTIFYING A VIRAL TARGET NUCLEIC ACID SEQUENCE | Non-Final OA | Bar-Ilan University |
| 18131262 | Methods, Compositions and Systems for Respiratory Virus Detection | Non-Final OA | Laboratory Corporation of America Holdings |
| 17922777 | RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING SARS-COV-2-SPIKE PROTEIN AND USES THEREOF | Non-Final OA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI |
| 17593747 | MULTI-RESPIRATORY VIRUS ANTIGEN-SPECIFIC T CELLS AND METHODS OF MAKING AND USING THE SAME THERAPEUTICALLY | Non-Final OA | Baylor College of Medicine |
| 18252212 | DNA CONSTRUCT FOR STABLY PRODUCING EMPTY CAPSIDS OF THE FOOT-AND-MOUTH DISEASE VIRUS IN MAMMALIAN CELLS; PROCESSES, USES, AND COMPOSITIONS THEREOF | Non-Final OA | National Research Council of Canada |
| 18008938 | Assay for the detection of the Cys-like protease (Mpro) of SARS-CoV-2 | Non-Final OA | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) |
| 18477785 | COMBINATION OF NOVEL VACCINES AGAINST ZIKA VIRUS AND DNA ANTIBODY CONSTRUCTS FOR USE AGAINST ZIKA VIRUS | Final Rejection | The Wistar Institute of Anatomy and Biology |
| 17609451 | DNA ENCODED IL-36 GAMMA AS AN ADJUVANT | Non-Final OA | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY |
| 18427737 | EBOLAVIRUS AND MARBURGVIRUS VACCINES | Non-Final OA | CureVac SE |
| 18538898 | RNA REPLICON FOR EXPRESSING AT CELL RECEPTOR OR AN ARTIFICIAL T CELL RECEPTOR | Non-Final OA | TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄTS MAINZ |
| 18564895 | SYSTEM, METHOD AND KITS FOR THE DETECTION OF BINDING AGENTS | Final Rejection | AB VALIDATION INC. FAS IVANO BIOSCIENCE |
| 17995401 | PHAGE-ENCODED AcrVIA1 FOR USE AS AN INHIBITOR OF THE RNA-TARGETING CRISPR-Cas13 SYSTEMS | Non-Final OA | THE ROCKEFELLER UNIVERSITY |
| 17273677 | HERV-K-DERIVED ANTIGENS AS SHARED TUMOR ANTIGENS FOR ANTI-CANCER VACCINE | Final Rejection | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) |
| 18031494 | ASSAY FOR MEASURING POTENCY OF GENE THERAPY DRUG PRODUCT | Non-Final OA | Prevail Therapeutics, Inc. |
| 17997009 | METHOD FOR DETECTING HBV GENOTYPE, OLIGONUCLEOTIDE AND KIT | Non-Final OA | LEADWAY (HK) LIMITED |
| 18005332 | COVID-19 Mucosal Antibody Assay | Non-Final OA | NantCell, Inc. |
| 18296027 | Diagnostic Tests | Non-Final OA | CTK Biotech, Inc. |
| 18247824 | IMMUNOGENIC FORMULATION CONTAINING A MODIFIED BCG STRAIN EXPRESSING AN ANDESVIRUS PROTEIN (ANDV) USEFUL FOR PREVENTING AND TREATING HANTA-ANDV VIRUS INFECTIONS | Non-Final OA | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE |
| 18030102 | LENTIVIRAL VECTORS ENABLING ROUTING ANTIGENS TO MHC-II PATHWAY AND INDUCING CD4+ AND CD8+ T-CELL RESPONSES IN A HOST | Non-Final OA | THERAVECTYS |
| 18246117 | COMPOUND FOR INCREASING EFFICACY OF VIRAL VECTORS | Non-Final OA | ABLEVIA BIOTECH GMBH |
| 18185344 | Biological Detection Sensor Chip and COVID-19 Test Kit | Non-Final OA | Xudong Cao |
| 18018488 | A DETECTION METHOD FOR VIRAL REPLICATION | Non-Final OA | Microbio Pty Ltd |
| 17955599 | RNA DETERMINANTS FOR DISTINGUISHING BETWEEN BACTERIAL AND VIRAL INFECTIONS | Final Rejection | MeMed Diagnostics Ltd. |
| 17619063 | COMPOSITIONS AND METHODS FOR TREATING AN IMMUNODEFICIENCY VIRUS INFECTION WITH A THERAPEUTIC INTERFERING PARTICLE | Non-Final OA | The J. David Gladstone Institutes, a testamentary trust established under the Will of J.David Gladst |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy